WSJ – Drug Firms Buy $67.5 Million Voucher to Speed FDA Review
BusinessWeek – Sanofi and Regeneron Pay $67.5 Million to Fast-Track a Cholesterol Drug
Pharmaceutical Online – Sanofi And Regeneron To Use Priority Review Voucher For Alirocumab
FierceBiotech – Sanofi, Regeneron pay $67M for a shortcut in the blockbuster PCSK9 race with Amgen
Nasdaq – BioMarin Sells Priority Review Voucher To Regeneron
SFGate Tech Chronicles – BioMarin sells special FDA voucher for $67.5 million
Medical Marketing and Media – Sanofi tightens PCSK9 race, exceeds Q2 expectations
Cantech Letter – What does BioMarin’s voucher sale mean to Knight Therapeutics?
thepharmaletter – Sanofi and Regeneron purchase FDA priority voucher for alirocumab
Seeking Alpha – Biotechs to use priority review voucher for cholesterol-lowering drug candidate
PMLive – Sanofi and Regeneron pay $67.5m to speed alirocumab review
FierceBiotech – How much would you pay for FDA special treatment?
Seattlepi – BioMarin sells special FDA voucher for $67.5 million
BioMarin – BioMarin Sells Priority Review Voucher for $67.5 Million
MarketWatch – BioMarin Sells Priority Review Voucher for $67.5 Million
BioTechSF – FDA punches BioMarin’s ‘golden ticket’ for speedy drug review
Nature Reviews – BioMarin nabs first paediatric priority review voucher
Vanrtage – Putting a value on US priority review vouchers
Zacks – BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up
SmartBrief – Sanofi, Regeneron buy BioMarin’s priority-review voucher for $67.5M
BioCentury – BioMarin sells Priority Review voucher
Evaluate – BioMarin Sells Priority Review Voucher for $67.5 Million
OrphanDrugNaut – Rare Diseases: BioMarin Sells FDA Priority Review Voucher for $67.5Â Million
Scrip Intelligence – Knight follows BioMarin’s lead; seeks voucher buyerÂ
Total Orphan Drugs – BioMarin Sells FDA Priority Review Worth $67.5 Million
Coconutoil.com – New Cholesterol Drug Approval to be Fast-tracked by FDA to Highest Bidder